CFTR

(redirected from Cystic fibrosis transmembrane conductance regulator)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Cystic fibrosis transmembrane conductance regulator: CFTR
  • noun

Synonyms for CFTR

the gene that is mutated in cystic fibrosis

References in periodicals archive ?
A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.
More than 1,800 different mutations have been discovered since the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsible for CF was discovered in 1989.
These two mutations cause specific chloride channels in the cell, known as the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) chloride channels, to malfunction.
CA/GT microsatellite alleles within the cystic fibrosis transmembrane conductance regulator (CFTR) gene are not generated by unequal crossing over.
They have also found that the gene -- called the cystic fibrosis transmembrane conductance regulator (CFTR) -- normally codes for the production of a tunnel-like protein through which cells excrete salty chloride ions (SN: 3/2/91, p.
At the recommended dose of one 125 mg delayed-release tablet taken orally, twice daily, Fulyzaq[TM] works to inhibit both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (C1-) channel, and the calcium-activated C1- channels (CaCC).
The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex in 2012, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
At the recommended dose of one 125 mg delayed-release tablet taken orally, twice daily, Crofelemer works to inhibit both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (C1-) channel, and the calcium-activated C1- channels (CaCC).
Identification of mutations in exons 1 through 8 of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
The protein, cystic fibrosis transmembrane conductance regulator (CFTR), usually helps cells maintain normal levels of chloride.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a decision has been made by the National Health Service (NHS) in England to fund KALYDECO[TM] (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
The first program, for which the milestone payment was received, is focused on the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.
Full browser ?